President Trump just announced another round of agreements with pharmaceutical companies under his “most-favored-nation” drug pricing initiative.
The nine new deals bring the total number of participating manufacturers to 26, covering nearly 90% of the branded-drug market.
The campaign targets a real problem. Many wealthy countries use price controls to pay far less for new medicines than Americans do.